$1.54
−3.14%Sep 25, 2026, 20:30 UTC
NervGen announced it will restate its audited annual financial statements for the year ended December 31, 2025 and its unaudited interim financial statements for the quarter ended June 30, 2026 to recognize non-cash accounting adjustments.
Source: